Patents by Inventor Joshua Odingo

Joshua Odingo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF
    Publication number: 20240150314
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Application
    Filed: October 2, 2023
    Publication date: May 9, 2024
    Inventors: Sampath Kumar ANANDAN, Joshua ODINGO, Heather Kay Webb HSU, Vincent FLORIO, Subramanyam Janardhan TANTRY, Athisayamani Jeyaraj DURAISWAMY
  • SPECIFIC SUBSTRATES AND PRODUCTS OF HSD17B13 AS MARKERS OF LIVER DISEASE AND BIOMARKERS FOR LIVER DISEASE TREATMENT
    Publication number: 20230416802
    Abstract: Provided are HSD17B13 substrates, reaction products, kits, and methods that include the HSD17B13 substrates or reaction products of the HSD17B13 substrates. Some embodiments include methods of treatment. Some such embodiments include determining an amount of an HSD17B13 substrate or of a reaction product of the HSD17B13 substrate in a sample from the subject to whom the HSD17B13 substrate has been administered.
    Type: Application
    Filed: November 3, 2021
    Publication date: December 28, 2023
    Inventors: Heather Kay Webb HSU, Vincent FLORIO, Michael CARLETON, Joshua ODINGO
  • Dichlorophenol HSD17B13 inhibitors and uses thereof
    Patent number: 11827619
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Grant
    Filed: May 10, 2023
    Date of Patent: November 28, 2023
    Assignee: INIPHARM, INC.
    Inventors: Sampath Kumar Anandan, Joshua Odingo, Heather Kay Webb Hsu, Vincent Florio, Subramanyam Janardhan Tantry, Athisayamani Jeyaraj Duraiswamy
  • QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF
    Publication number: 20230286923
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Application
    Filed: July 23, 2021
    Publication date: September 14, 2023
    Inventors: Joshua ODINGO, Sampath Kumar ANANDAN, Heather Kay Webb HSU, Vincent FLORIO, Subramanyam Janardhan TANTRY, Athisayamani Jeyaraj DURAISWAMY, Bharathi Mohan KUPPUSAMY
  • THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF
    Publication number: 20230278978
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Application
    Filed: July 23, 2021
    Publication date: September 7, 2023
    Inventors: Joshua ODINGO, Sampath Kumar ANANDAN, Heather Kay Webb HSU, Vincent FLORIO, Subramanyam Janardhan TANTRY, Athisayamani Jeyaraj DURAISWAMY
  • DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF
    Publication number: 20230278981
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Application
    Filed: May 10, 2023
    Publication date: September 7, 2023
    Inventors: Sampath Kumar ANANDAN, Joshua ODINGO, Heather Kay Webb HSU, Vincent FLORIO, Subramanyam Janardhan TANTRY, Athisayamani Jeyaraj DURAISWAMY
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
    Publication number: 20230183239
    Abstract: Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.
    Type: Application
    Filed: March 23, 2022
    Publication date: June 15, 2023
    Inventors: William Michael GALLATIN, Joshua ODINGO, Gregory N. DIETSCH, Vincent FLORIO, Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY
  • HSD17B13 INHIBITORS AND USES THEREOF
    Publication number: 20230150940
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Application
    Filed: April 16, 2021
    Publication date: May 18, 2023
    Inventors: Joshua ODINGO, Heather Kay Webb HSU, Vincent FLORIO, Subramanyam Janardhan TANTRY, Rajendra KRISTAM, Athisayamani Jeyara DURAISWAMY
  • ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF
    Publication number: 20210023234
    Abstract: Disclosed herein are ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) complexes and synthetic molecules that interact with an ENPP protein. In some embodiments, also disclosed herein are modified ENPP polypeptides in complex with a synthetic molecule described herein.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Inventors: William Michael GALLATIN, Gregory N DIETSCH, Joshua ODINGO, Vincent FLORIO
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
    Publication number: 20200291024
    Abstract: Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.
    Type: Application
    Filed: August 31, 2018
    Publication date: September 17, 2020
    Inventors: William Michael GALLATIN, Joshua ODINGO, Gregory N. DIETSCH, Vincent FLORIO
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF
    Publication number: 20190282703
    Abstract: Disclosed herein are ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) complexes and synthetic molecules that interact with an ENPP protein. In some embodiments, also disclosed herein are modified ENPP polypeptides in complex with a synthetic molecule described herein.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 19, 2019
    Inventors: William Michael GALLATIN, Gregory N. DIETSCH, Joshua ODINGO, Vincent FLORIO
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 7176229
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: February 13, 2007
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence Edward Burgess, John Joseph Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20060074123
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: November 7, 2005
    Publication date: April 6, 2006
    Applicant: ICOS CORPORATION
    Inventors: Timothy Martins, Kerry Fowler, Joshua Odingo, Edward Kesicki, Amy Oliver, Laurence Burgess, John Gaudino, Zachary Jones, Bradley Newhouse, Stephen Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6998416
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: February 14, 2006
    Assignee: Icos Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20040152754
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: January 15, 2004
    Publication date: August 5, 2004
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodie sterase inhibitors
    Patent number: 6716871
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: April 6, 2004
    Assignee: Icos Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E Burgess, John J. Gaudino, Zachary S Jones, Bradley J Newhouse, Stephen T. Schlachter
  • CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS
    Publication number: 20040023945
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: May 17, 2002
    Publication date: February 5, 2004
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6680336
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: January 20, 2004
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6500856
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: December 31, 2002
    Assignee: Icos Corporation
    Inventors: Kerry W. Fowler, Amy Oliver, Joshua Odingo
  • Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
    Patent number: 6486186
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 26, 2002
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo